Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Cancer Discov. 2019 Apr 16;9(5):587–604. doi: 10.1158/2159-8290.CD-18-1196

Figure 4. Clonal predominance in alternating therapy.

Figure 4.

Depiction of clonal predominance switching during alternating treatment with 2 different EGFR TKI therapies to maintain a steady state population until outgrowth of a clonal population resistant to both therapies occurs, at which point a new therapy would be employed.